Brief: Spago Nanomedical Updates On Preclinical Studies Of Tumorad
19/05/2020 08:04
May 19 (Reuters) - Spago Nanomedical AB (publ) SPAGO.TE :
* PRECLINICAL STUDIES SHOW TUMORAD ACCUMULATES IN TUMORS TO
AN
EXTENT WHICH MEANS SUBSTANCE HAS GOOD POTENTIAL TO BECOME
CLINICALLY USEFUL
Source text for Eikon: [ID:https://cisn.co/3bQtDNn]
Further company coverage: SPAGO.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))